Source:http://linkedlifedata.com/resource/pubmed/id/11244301
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2001-3-13
|
pubmed:abstractText |
Glucocorticoids inhibit stimulus-induced T-cell proliferation, an early and essential parameter of cellular immunity. It was recently found however that physiological concentrations of glucocorticoids can also accelerate, not only inhibit, rat T-cell mitogenesis. We investigated mechanism(s) underlying mitogenic actions of glucocorticoids on anti-T-cell receptor (TCR)- and concanavalin A (Con A)-induced T-cell proliferation. Surprisingly, the ability of the glucocorticoid corticosterone (CORT) to either enhance or inhibit T-cell proliferation was found to depend primarily on the cell density and the timing of the cultures. At cell densities up to 1 x 10(5) cells/well (i.e. 'low' density), CORT inhibited T-cell proliferation irrespective of the culture time. In contrast, at cell densities of 2 x 10(5) cells/well and higher ('high' density), CORT potently stimulated T-cell mitogenesis during the first 2-3 culture days, but subsequently inhibited the proliferative response after 5-7 days. The glucocorticoid receptor antagonist RU486 completely abolished the effects of CORT. However, production of the main T cell growth factor interleukin (IL)-2 was inhibited by CORT at both 'low' and 'high' cell densities. In addition, irrespective of cell density, T-cell mitogenesis under either control conditions or in presence of CORT was completely blocked by an anti-IL-2-receptor-alpha-chain (IL-2Ralpha) antibody, indicating that T-cell proliferation was dependent on the IL-2 pathway. Immunofluorescence staining of IL-2Ralpha on CD4+ cells after 2-3 days in culture was increased by CORT, but only on cells cultured at 'high' density. Thus, glucocorticoids increase T-cell responsiveness to IL-2 under conditions of 'high' cell density only. We conclude that glucocorticoids may contribute to a more efficient early stage of cellular immune responses under conditions of intimate cell-to-cell contact (i.e. 'high' cell density), a situation likely to be present in vivo, for instance in lymph nodes. Thus, these findings are relevant to our understanding of the glucocorticoid control of immune function.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Concanavalin A,
http://linkedlifedata.com/resource/pubmed/chemical/Corticosterone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0028-3835
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2001 S. Karger AG, Basel.
|
pubmed:issnType |
Print
|
pubmed:volume |
73
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
139-48
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11244301-Animals,
pubmed-meshheading:11244301-Antibodies, Monoclonal,
pubmed-meshheading:11244301-CD4-Positive T-Lymphocytes,
pubmed-meshheading:11244301-Cell Count,
pubmed-meshheading:11244301-Cells, Cultured,
pubmed-meshheading:11244301-Concanavalin A,
pubmed-meshheading:11244301-Corticosterone,
pubmed-meshheading:11244301-Dose-Response Relationship, Drug,
pubmed-meshheading:11244301-Lymphocyte Activation,
pubmed-meshheading:11244301-Male,
pubmed-meshheading:11244301-Rats,
pubmed-meshheading:11244301-Rats, Wistar,
pubmed-meshheading:11244301-Receptors, Antigen, T-Cell,
pubmed-meshheading:11244301-Receptors, Antigen, T-Cell, alpha-beta,
pubmed-meshheading:11244301-Spleen,
pubmed-meshheading:11244301-T-Lymphocytes,
pubmed-meshheading:11244301-Time Factors
|
pubmed:year |
2001
|
pubmed:articleTitle |
Bidirectional effects of corticosterone on splenic T-cell activation: critical role of cell density and culture time.
|
pubmed:affiliation |
Max Planck Institute of Psychiatry, Section of Neuropsychopharmacology, Munich, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|